Eversept Partners LP Increases Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Eversept Partners LP grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 27.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 719,836 shares of the biopharmaceutical company’s stock after purchasing an additional 154,934 shares during the period. Celldex Therapeutics makes up approximately 1.6% of Eversept Partners LP’s holdings, making the stock its 12th largest position. Eversept Partners LP owned approximately 1.09% of Celldex Therapeutics worth $18,190,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in CLDX. Invesco Ltd. increased its holdings in shares of Celldex Therapeutics by 2.1% during the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock valued at $1,064,000 after acquiring an additional 871 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 878 shares during the last quarter. Swiss National Bank raised its stake in shares of Celldex Therapeutics by 1.2% in the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock worth $2,964,000 after purchasing an additional 1,400 shares during the last quarter. KBC Group NV lifted its holdings in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 1,647 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its position in shares of Celldex Therapeutics by 6.1% during the fourth quarter. MetLife Investment Management LLC now owns 39,620 shares of the biopharmaceutical company’s stock valued at $1,001,000 after buying an additional 2,288 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CLDX. Morgan Stanley initiated coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an “overweight” rating and a $46.00 price target on the stock. The Goldman Sachs Group reduced their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. UBS Group assumed coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $54.33.

Celldex Therapeutics Stock Up 3.5 %

Shares of CLDX opened at $18.94 on Tuesday. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -7.37 and a beta of 1.59. The company has a 50 day moving average of $19.47 and a two-hundred day moving average of $23.74. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.